Vascular response after Zilver PTX stent implantation for superficial femoral artery lesions: serial optical coherence tomography findings at 6 and 12 months

J Endovasc Ther. 2015 Feb;22(1):41-7. doi: 10.1177/1526602814566577.

Abstract

Purpose: To compare the vascular response after paclitaxel-coated nitinol drug-eluting stent (Zilver PTX) implantation for superficial femoral artery lesions after 6 and 12 months using optical coherence tomography (OCT).

Methods: Serial OCT examinations were performed in 5 patients (4 men; mean age 78.4 ± 6.8 years) with 9 Zilver PTX stents at 6- and 12-month follow-up. Variables evaluated included neointimal thickness and apposition on each strut, the incidence of extrastent lumen (ESL), peristrut low-intensity area (PLIA), and neovascularization at 1-mm intervals.

Results: A total of 249 matched cross-section images were evaluated and included 4788 and 4826 struts at 6 and 12 months, respectively. Mean neointimal thickness significantly increased from 480 to 540 µm between 6 and 12 months (p < 0.001). The percentage of uncovered struts tended to decrease at 12 months (3% vs. 2.3%, p = 0.054), whereas the percentage of malapposed struts were similar at both examinations (0.2% vs. 0.2%, p > 0.99). Although the incidence of ESL in cross sections was not different (35% vs. 31%, p = 0.29), median ESL area significantly increased from 6 to 12 months [0.12 (0.04-0.36) vs. 0.31 (0.14-0.59) mm(2), p = 0.003)]. The presence of PLIA (29% vs. 44%, p < 0.001) and neovascularization (14% vs. 27%, p < 0.001) increased from 6 to 12 months.

Conclusion: These findings suggest that delayed vascular healing and persistent peristent inflammation may be present even at 12 months after Zilver PTX implantation.

Keywords: drug-eluting stent; endovascular therapy; inflammation; neointimal thickness; neovascularization; optical coherence tomography; stent apposition; superficial femoral artery; vascular response.

Publication types

  • Comparative Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alloys / administration & dosage
  • Cardiovascular Agents / administration & dosage
  • Drug-Eluting Stents* / adverse effects
  • Female
  • Femoral Artery / pathology*
  • Follow-Up Studies
  • Humans
  • Male
  • Neointima*
  • Paclitaxel / administration & dosage
  • Peripheral Arterial Disease / diagnosis*
  • Peripheral Arterial Disease / therapy*
  • Predictive Value of Tests
  • Retrospective Studies
  • Risk Factors
  • Sensitivity and Specificity
  • Tomography, Optical Coherence* / methods
  • Treatment Outcome

Substances

  • Alloys
  • Cardiovascular Agents
  • nitinol
  • Paclitaxel